ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
PRNewsWire
·
2026-06-01
·
via The Tech Buzz - Press Releases
CHICAGO, May 31, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cance…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。